In October 2019, AevisBio entered into a Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging (NIA), part of the National Institutes of Health (NIH) to develop potential new treatments for neurological conditions, such as Alzheimer’s disease and Parkinson’s disease.

In July of 2019, AevisBio and Korea Research Institute of Bioscience & Biotechnoogy (KRIBB) announced a collaboration to discover, develop, and commercialize therapies for treating disease of aging, including Parkinson’s disease.

In June of 2020, AevisBio and Korea Research Institute of Standards and Science (KRISS) announced a collaboration to develop technologies for treating infectious disease especially focused on COVID19.

In January 2021, AevisBio signed a Cooperative research agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) for the joint new drug development.

In January 2021, AevisBio and Institut Pasteur Korea (IPK) were selected a new drug development program from National Research Foundation of Korea. This program will enable AevisBio to open the Chemical Research Center at IPK in Pangyo, Korea, for the further development of TPD platform technologies.

In June of 2021, AevisBio, Institut Pasteur Korea (IPK) and National Institute on Aging (NIA) signed a Cooperative research agreement to develop potential new treatments for infectious diseases.

In December 2022, AvisBio and the University of Cagliari announced a collaboration to verify efficacy and drug concentration in PD animal models based on AEV003.

In November of 2021, AevisBio and Korea Research Institute of Chemical Technology (KRICT) signed a Cooperative research agreement to develop potential new treatments for neoplastic diseases.

In December of 2021, AevisBio and Yonsei University (Severance) signed a Cooperative research agreement to develop potential new treatments for neurological conditions, such as Alzheimer’s disease.